Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Offers up to $470K in Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Canadian diagnostics developer Miraculins aims to gain up to C$500,500 ($469,200) in gross proceeds through a private placement of as many as 7,150,000 units priced at C$.07 per unit.

The firm, which trades on the TSX Venture Exchange, said on Tuesday that it plans to use the proceeds from the placement for research and development and for corporate working capital.

The units in the placement will include one common share and one share purchase warrant, priced at C$.10. The warrants will be callable by the company if the share price rises above C$.14 for any 20 out of 30 consecutive trading days.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.